Capitol TrackerExecutive changes
When a company's CEO, CFO or another officer or director leaves or joins, it has to tell the SEC in an 8-K (Item 5.02), usually within four business days. Filings from the last 14 days, senior roles first. The text is quoted from the filing. Where we have it, insider selling in the 60 days before is shown from Form 4 filings. A sale before a departure is not evidence of anything on its own. Not investment advice.
“On October 30, 2026, Kim Roy notified The Children's Place, Inc. (the “Company”) of her resignation from the Company’s board of directors (the “Board”), effective immediately. Ms. Roy’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. On November 1, 2026, Muhammad Asif Seemab resigned as President and Interim Chief Executive Officer of the Company, and Muhammad Umair resigned as Chi…”
“Resignation of Thomas Spruce as Director, Chief Operations Officer, Chief Financial Officer, and Secretary Effective as of October 29, 2026, Thomas Spruce resigned as Director, Chief Operations Officer, Chief Financial Officer, and Secretary of Electronic Servitor Publication Network, Inc. (the “ Company ”). Mr. Spruce’s resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices. Appointment of Peter Hager as I…”
“- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective November 2, 2026, the Board of Directors (the “Board”) of Creatd, Inc. (the “Company”) appointed Claudia Albelais as Chief Financial Officer and principal financial officer of the Company. Effective upon Ms. Albelais’s appointment, Jeremy Frommer ceased serving as the Company’s principal financial officer. Ms. Albelais,…”
“Appointment of Chief Executive Officer On November 1, 2026, the Board of Directors (“Board”) of Anavex Life Sciences Corp. (“Anavex” or the “Company”), appointed Terrie Kellmeyer, Ph.D. as the Company’s Chief Executive Officer (“CEO”) and President effective immediately. Dr. Kellmeyer, age 59, has served as the Company’s Interim CEO since May 4, 2026. Dr. Kellmeyer possesses over 30 years of experience in the pharmaceutical industry and has held executive leadership positions…”
“JP Aubin Appointed Vice Chairman of BGC Group, Inc. On November 3, 2026, BGC Group, Inc. (“BGC” or the “Company”) announced that JP Aubin will be appointed Vice Chairman of BGC, effective at the close of business on December 31, 2026. In connection with the appointment, except as if and when otherwise designated by the Co-Chief Executive Officers (“Co-CEOs”) of the Company, Mr. Aubin will step down from his current roles at the Company and its subsidiaries, including as Co-CE…”
“Erie Indemnity Company (the “Company”) announced that Timothy G. NeCastro, its President and Chief Executive Officer, retired November 2, 2026. The Company previously announced that Mr. NeCastro would retire on December 31, 2026. Mr. NeCastro’s retirement date was accelerated for personal reasons. The Company also announced that Brian W. Bolash has been appointed as Interim President and Chief Executive Officer of the Company effective November 3, 2026. Mr. Bolash, age 61, ha…”
“After more than five years of exemplary service, on October 30, 2026, Timothy “Tod” White informed the Company that he will retire from his current position as President of the Company, effective as of December 31, 2026. Mr. White has agreed to remain as a consultant to the Company from January 1, 2027 through June 30, 2027 to ensure an orderly transition and continuity of operations. Yuling Luo, Ph.D., Founder, Chief Executive Officer, and Chair of the Company said, “Tod has…”
“- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 28, 2026, Elena Gomez notified the Company of her decision to step away as the Company’s President and Chief Financial Officer, effective December 31, 2026 (the “Effective Date”). Ms. Gomez’s resignation was not due to any disagreement relating to the Company’s management, policies or practices. Following the Effective…”
“On November 3, 2026, Concentrix Corporation (the “Company”) announced that Chinnu Susan Varghese will succeed Andre Valentine as the Company’s Chief Financial Officer, effective December 1, 2026. Mr. Valentine will continue to serve as Chief Financial Officer in the near term and is expected to remain with the Company through the second quarter of fiscal 2027 to provide transition support for Ms. Varghese. Ms. Varghese will join the Company on November 9, 2026 and assume the…”
“Appointment of Chief Executive Officer On October 28, 2026, the Board of Directors (the “Board”) of Picard Medical, Inc., a Delaware company (the “Company”) appointed Richard Fang, Ph.D., as the Company’s Chief Executive Officer on a permanent, full-time basis, effective as of the same date. Dr. Fang has served as Interim Chief Executive Officer since June 18, 2026 and will continue to serve as Chairman of the Board. Dr. Fang, age 60, has served on the Board since September 2…”